Nervous System News and Research

Latest Nervous System News and Research

Scientists demonstrate how second set of cells carry signals from the inner ear to the brain

Deep in the ear, 95 percent of the cells that shuttle sound to the brain are big, boisterous neurons that, to date, have explained most of what scientists know about how hearing works. Whether a rare, whisper-small second set of cells also carry signals from the inner ear to the brain and have a real role in processing sound has been a matter of debate.

23 Oct 2009

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the results of an animal study that further demonstrates the company’s Phase II oncology drug, Archexin™, as having the potential to target and treat multiple life-threatening cancers.

23 Oct 2009

Families of Spinal Muscular Atrophy and Repligen partner to develop a treatment for SMA

Families of Spinal Muscular Atrophy (FSMA) announced today that it has entered into a groundbreaking exclusive license agreement with Repligen Corporation for the development of a potential treatment of Spinal Muscular Atrophy (SMA).

23 Oct 2009

Intellectual property covering compounds that have utility in treating SMA licensed

Repligen Corporation announced today that it has entered into an exclusive license agreement with Families of Spinal Muscular Atrophy (FSMA) for intellectual property covering compounds which may have utility in treating Spinal Muscular Atrophy (SMA).

23 Oct 2009

KemPharm commences KP106 Phase 1 clinical trial for ADHD

KemPharm, Inc. today announced that it has commenced a Phase 1 clinical trial in healthy volunteers of its novel prodrug compound, KP106, which is in development for the treatment of attention-deficit hyperactivity disorder (ADHD). KP106, a new chemical entity (NCE) composed of d-amphetamine and a ligand, is the lead investigational candidate from KemPharm’s proprietary ligand activated therapy (LAT) platform, which creates improved versions of FDA-approved drugs. KemPharm began the KP106 program in 2007 and has initiated the Phase 1 clinical trial of this candidate in less than 24 months.

22 Oct 2009

Drugs affecting the central nervous system effective against fibromyalgia, study finds

People suffering from fibromyalgia have reduced activity in the parts of the brain that inhibit the experience of pain. Drugs that affect the CNS can be effective against the disease, and are thought to be even more so if administered early in its course. This according to a new thesis from the Swedish medical university Karolinska Institutet.

22 Oct 2009

FDA extends Acorda Therapeutics' Fampridine-SR PDUFA goal date

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the U.S. Food and Drug Administration (FDA) has extended the PDUFA goal date for its review of the New Drug Application (NDA) for Fampridine-SR to January 22, 2010. The original Prescription Drug User Fee Act (PDUFA) date for this priority review application was October 22, 2009.

22 Oct 2009

PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial

PacificGMP, the leader in single-use bioprocessing for development and manufacturing for its client partners, announced that ArmaGen Technologies has selected it to produce its proprietary protein for a Phase 1 clinical trial.

22 Oct 2009

Pharmos announces results of its Phase 2b Dextofisopam trial

Pharmos Corporation (Pink Sheets: PARS); on September 14, 2009, Pharmos announced the results of its Phase 2b Dextofisopam trial for the treatment of diarrhea predominant and alternating diarrhea and constipation irritable bowel syndrome.

22 Oct 2009

Cephalon announces receipt of a Paragraph IV Certification Notice Letter regarding ANDA

Cephalon, Inc. (Nasdaq: CEPH) today announced receipt of a Paragraph IV Certification Notice Letter on October 20, 2009 regarding an Abbreviated New Drug Application (ANDA) submitted to the U.S. Food and Drug Administration (FDA) by Teva Pharmaceuticals USA, Inc. requesting approval to market and sell a generic version of the 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths of NUVIGIL® (armodafinil) Tablets [C-IV].

22 Oct 2009

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

A group led by Dr. Dieter Br-mme at the University of British Columbia has demonstrated that glycosaminoglycans (GAGs) contribute to skeletal abnormalities in patients with lysosomal storage diseases. Their report can be found in the November 2009 issue of The American Journal of Pathology.

21 Oct 2009

Researchers show how to make stem cell therapies safer for spinal injury patients

Animal research is suggesting new ways to aid recovery after spinal cord injury. New studies demonstrate that diet affects recovery rate and show how to make stem cell therapies safer for spinal injury patients. The findings were presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world's largest source of emerging news on brain science and health.

21 Oct 2009

Research may facilitate improved understanding of music perception in human nervous system

Music serves as a natural and non-invasive intervention for patients with severe neurological disorders to promote long-term memory, social interaction and communication. However, there is currently no plausible explanation of its neural basis for why and how music affects physical and psychosocial responses.

21 Oct 2009

Dainippon Sumitomo Pharma acquires Sepracor

Dainippon Sumitomo Pharma Co., Ltd. (“DSP”) and Sepracor Inc. today announce the successful completion of DSP’s acquisition of Sepracor for US$23.00 per share in cash. DSP completed the acquisition through a cash tender offer and by exercising an option to acquire additional shares directly from Sepracor followed by a short-form merger of an indirect wholly-owned subsidiary of DSP with and into Sepracor on October 20, 2009. Sepracor is now an indirect wholly-owned subsidiary of DSP.

21 Oct 2009

Patients with chronic hepatitis C can benefit by drinking coffee

Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease progression than non-coffee drinkers according to a new study led by Neal Freedman, Ph.D., MPH, from the National Cancer Institute (NCI).

20 Oct 2009

Positive results from KAI Pharmaceuticals' pain therapeutic program

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, announced positive preclinical results from its program targeting the gamma protein kinase C (PKC) pathway for the development of novel therapies for pain.

20 Oct 2009

Targacept presents data from Phase 2b clinical trial of TC-5214

Targacept, Inc., a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics-, today announced the presentation of data from its recently completed Phase 2b clinical trial of TC-5214 as an augmentation (add-on) treatment in subjects with major depressive disorder, or MDD, who did not respond adequately to first-line treatment with the representative SSRI citalopram hydrobromide.

20 Oct 2009

Human neural stem cells protect cone photoreceptors: StemCells preclinical data

StemCells, Inc. announced today new preclinical data showing that its human neural stem cells protect cone photoreceptors (cones) in the eye from progressive degeneration and preserve visual function long term.

20 Oct 2009

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Merck Frosst Canada Ltd. is pleased to announce that (Pr)ISENTRESS(R) (raltegravir) is now indicated for use in treatment-naïve HIV-1 infected adults in combination with other antiretroviral agents.

20 Oct 2009

Aspect Medical Systems to present a complete family of BIS monitoring technologies at ASA meeting

The American Society of Anesthesiologists (ASA) Annual Meeting will feature 62 scientific presentations that reference BIS® monitoring when it convenes on October 17-21, 2009 in New Orleans. BIS-related research will cover a broad range of applications for BIS monitoring, including initial results from studies conducted as part of a comparative effectiveness research collaboration with the Cleveland Clinic as well as findings from a study evaluating use of a Composite Variability Index (CVI) that is based on BIS parameters.

20 Oct 2009

Nervous System News and Research

Latest Nervous System News and Research

Scientists demonstrate how second set of cells carry signals from the inner ear to the brain

Archexin has potential to target and treat multiple life-threatening cancers, finds new study

Families of Spinal Muscular Atrophy and Repligen partner to develop a treatment for SMA

Intellectual property covering compounds that have utility in treating SMA licensed

KemPharm commences KP106 Phase 1 clinical trial for ADHD

Drugs affecting the central nervous system effective against fibromyalgia, study finds

FDA extends Acorda Therapeutics' Fampridine-SR PDUFA goal date

PacificGMP selected by ArmaGen Technologies to produce its proprietary protein for a Phase 1 clinical trial

Pharmos announces results of its Phase 2b Dextofisopam trial

Cephalon announces receipt of a Paragraph IV Certification Notice Letter regarding ANDA

Contribution of glycosaminoglycans to skeletal abnormalities in patients with lysosomal storage diseases demonstrated

Researchers show how to make stem cell therapies safer for spinal injury patients

Research may facilitate improved understanding of music perception in human nervous system

Dainippon Sumitomo Pharma acquires Sepracor

Patients with chronic hepatitis C can benefit by drinking coffee

Positive results from KAI Pharmaceuticals' pain therapeutic program

Targacept presents data from Phase 2b clinical trial of TC-5214

Human neural stem cells protect cone photoreceptors: StemCells preclinical data

Merck Frosst Canada announces the use of ISENTRESS for treating HIV-1 infected adults

Aspect Medical Systems to present a complete family of BIS monitoring technologies at ASA meeting

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Nervous System News and Research

Latest Nervous System News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in